Gastrointestinal stromal tumor (GIST) is a rare group of tumors that arise from the interstitial cells of Cajal in the gastrointestinal tract, which are responsible for controlling peristalsis. These tumors can occur in various sites along the gastrointestinal tract, including the stomach, small intestine, and colon. GISTs are classified as mesenchymal tumors that can vary in size and malignancy, from benign to highly malignant forms. The underlying mechanism of their development is a mutation in genes responsible for the regulation of cell proliferation and apoptosis, which leads to abnormal cell proliferation.
History of the disease and interesting historical facts
Gastrointestinal stromal tumors were first described in the mid-20th century, but their full understanding came only with the development of molecular biology and genetics in the late 1990s. An important step in the study of GIST was the discovery of the role of a mutation in the C-KIT gene, which was documented in 1998. This finding not only gave impetus to further research, but also opened up new possibilities for targeted therapy. For decades, students of Friedrich Gottlieb, one of the pioneering researchers, studied these tumors, but it was not until 2000 that systematic clinical studies were launched that allowed us to understand the various clinical manifestations and outcomes of the disease.
Epidemiology
According to studies, gastrointestinal stromal tumors occur in 10-20 patients per 1 million population annually. Although GISTs can occur in any part of the gastrointestinal tract, the greatest number of cases are registered in the stomach and small intestine. According to statistics, the average age of patients with this disease is about 60 years, but tumors can also be diagnosed in much younger patients. Gender differences are also observed: a predisposition of men to this pathology is clearly distinguished compared to women, but the exact reasons for this are still a subject of research.
Genetic predisposition to this disease
Mutations in several genes play a key role in the genesis of gastrointestinal stromal tumors, the most well-known of which are the C-KIT and PDGFRA genes. About 85% cases of GIST are associated with mutations in C-KIT, which encode tyrosine kinase receptors. Other mutations in the PDGFRA genes (platelet-derived growth factor action platform) can also be identified, but in fewer cases. These molecular changes lead to the activation of various signaling pathways, which ultimately promotes the growth and proliferation of stromal cells.
Risk factors for the development of this disease
Among the factors associated with gastrointestinal stromal tumors, the following stand out:
- Genetic predisposition – having a family history may increase the risk of developing GIST.
- Chronic diseases – such as Peyronie's disease or neurofibromatosis (Neufon's syndrome).
- Chemical exposure – Investments in certain chemical compounds may be associated with an increased risk of developing these tumors.
- Older age – the risk increases with age, making older patients more vulnerable.
Diagnosis of this disease
Diagnosis of gastrointestinal stromal tumors includes several stages:
- Main symptoms: include stomach pain, weight loss, specific gastrointestinal bleeding and anemia.
- Laboratory tests: complete blood counts, biochemical analysis, and specific markers such as thiozide levels.
- Radiological examinations: CT and MRI play an important role in visualizing the tumor and its anatomical features.
- Other types of diagnostics: endoscopic examinations and biopsy for histological examination of a tissue sample.
- Differential diagnosis: Other tumors and benign lesions must be excluded by careful evaluation.
Treatment
Treatment of gastrointestinal stromal tumors is based on the following approaches:
- General treatment: In the presence of metastases or a malignant tumor, complete surgical removal may be indicated.
- Pharmacological treatment: The use of imatinib, terosinib and other targeted drugs is aimed at blocking the C-KIT pathway.
- Surgical treatment: The most common method is tumor resection, taking into account its location and size.
- Other types of treatment: In some cases, radiation therapy or supportive care may be required during the rehabilitation phase.
List of medications used to treat this disease
- Imatinib (Gleevec)
- Dastinib (Sprycel)
- Nelotinib (Tasigna)
- Ryzotinib (Rydapt)
Disease monitoring
Monitoring of gastrointestinal stromal tumors includes the following key aspects:
- Control stages: Regular check-ups with an oncologist, blood tests and radiological examinations to assess the patient's condition after treatment.
- Forecast: Depending on the stage of the tumor and its subtype, the prognosis can vary significantly.
- Complications: relapses, metastases, and side effects from treatment are possible.
Age-related features of the disease
Gastrointestinal stromal tumors have age-related characteristics that manifest as follows:
- In children and adolescents the disease occurs much less frequently and, as a rule, has a more aggressive course.
- In adults, especially those over 50 years of age, tumors may present less dramatically and be difficult to detect in the early stages.
- In older patients, the risk of comorbidities increases, which complicates the diagnosis and treatment of GIST.
Questions and Answers
- What are the main symptoms of GIST? The main symptoms are stomach pain, weight loss, resistance to food and weakness, which may be associated with abnormalities in the gastrointestinal tract.
- How is GIST diagnosed? Diagnosis is based on laboratory tests, radiological examinations and biopsy, which allows for accurate confirmation of the presence of a tumor.
- What treatment is recommended for GIST? Treatment includes surgery, chemotherapy using targeted drugs and, if necessary, radiation.
- What do you need to know about the prognosis for GIST? The prognosis depends on the stage of the disease, the size of the tumor and the presence of metastases; early diagnosis significantly improves outcomes.
- Is it possible to prevent GIST? There is no complete prevention, but regular medical examinations and consideration of risk factors can help in early detection of the disease.
In conclusion, Dr. Oleg Korzhikov recommends the following for patients with gastrointestinal stromal tumors: "If you suspect GIST, do not delay visiting a doctor. Be sure to conduct all necessary tests and be attentive to your own condition. Having information about your health, you will be able to promptly respond to any changes."
